摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-9-benzyl-6-cyclohexylmethoxy-9H-purine | 674795-26-7

中文名称
——
中文别名
——
英文名称
2-amino-9-benzyl-6-cyclohexylmethoxy-9H-purine
英文别名
9-benzyl-6-(cyclohexylmethoxy)purin-2-amine
2-amino-9-benzyl-6-cyclohexylmethoxy-9H-purine化学式
CAS
674795-26-7
化学式
C19H23N5O
mdl
——
分子量
337.425
InChiKey
HJOPOBCRSPXAOU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    78.8
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    2-amino-9-benzyl-6-cyclohexylmethoxy-9H-purine盐酸copper(l) iodide 、 palladium 10% on activated carbon 、 氢气 、 palladium diacetate 、 caesium carbonate溶剂黄146 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 20.0~200.0 ℃ 、101.33 kPa 条件下, 反应 13.67h, 生成 3-(2-amino-6-cyclohexylmethoxy-9H-purin-8-yl)-2-methylphenol
    参考文献:
    名称:
    8-Substituted O6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode
    摘要:
    Evaluation of the effects of purine C-8 substitution within a series of CDK1/2-selective O-6-cyclohexylmethylguanine derivatives revealed that potency decreases initially with increasing size of the alkyl substituent. Structural analysis showed that C-8 substitution is poorly tolerated, and to avoid unacceptable steric interactions, these compounds adopt novel binding modes. Thus, 2-amino-6-cyclohexylmethoxy-8-isopropyl-9H-purine adopts a "reverse" binding mode where the purine backbone has flipped 180 degrees. This provided a novel lead chemotype from which we have designed more potent CDK2 inhibitors using, in the first instance, quantum mechanical energy calculations. Introduction of an ortho-tolyl or ortho-chlorophenyl group at the purine C-8 position restored the potency of these "reverse" binding mode inhibitors to that of the parent 2-amino-6-cyclohexylmethoxy-9H-purine. By contrast, the corresponding 8-(2-methyl-3-sulfamoylphenyl)-purine derivative exhibited submicromolar CDK2-inhibitory activity by virtue of engineered additional interactions with Asp86 and Lys89 in the reversed binding mode, as confirmed by X-ray crystallography.
    DOI:
    10.1021/jm401555v
  • 作为产物:
    描述:
    溴甲苯O6-环甲基己基鸟嘌呤potassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 12.0h, 以29%的产率得到2-amino-9-benzyl-6-cyclohexylmethoxy-9H-purine
    参考文献:
    名称:
    8-Substituted O6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode
    摘要:
    Evaluation of the effects of purine C-8 substitution within a series of CDK1/2-selective O-6-cyclohexylmethylguanine derivatives revealed that potency decreases initially with increasing size of the alkyl substituent. Structural analysis showed that C-8 substitution is poorly tolerated, and to avoid unacceptable steric interactions, these compounds adopt novel binding modes. Thus, 2-amino-6-cyclohexylmethoxy-8-isopropyl-9H-purine adopts a "reverse" binding mode where the purine backbone has flipped 180 degrees. This provided a novel lead chemotype from which we have designed more potent CDK2 inhibitors using, in the first instance, quantum mechanical energy calculations. Introduction of an ortho-tolyl or ortho-chlorophenyl group at the purine C-8 position restored the potency of these "reverse" binding mode inhibitors to that of the parent 2-amino-6-cyclohexylmethoxy-9H-purine. By contrast, the corresponding 8-(2-methyl-3-sulfamoylphenyl)-purine derivative exhibited submicromolar CDK2-inhibitory activity by virtue of engineered additional interactions with Asp86 and Lys89 in the reversed binding mode, as confirmed by X-ray crystallography.
    DOI:
    10.1021/jm401555v
点击查看最新优质反应信息